Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma

The research of E.R.S.C. and A.S.K. is funded by Arnold Ventures. The funders had no role in the design and conduct of the study, collection, analysis and interpretation of the data, preparation, review or approval of the manuscript, or decision to submit the manuscript for publication. The authors thank N. Mehta-Shah for discussions regarding romidepsin.

Comments (0)

No login
gif